Plasma exchange and heart-liver transplantation in a patient with homozygous familial hypercholesterolemia

Clinical Transplantation

Volumn 15, Issue 6, 2001, Pages 432-436

  Offstad, Jon ^a,b   Schrumpf, Erik ^a   Geiran, Odd ^a   Odd Soreide D ^b   Simonsen, Svein ^a  

^a Department of Cardiology ^*  (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Familial hypercholesterolemia; Heart liver transplantation; Plasma exchange

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; THYROXINE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DIET THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GRAFT REJECTION; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART TRANSPLANTATION; HEART VALVE REPLACEMENT; HOMOZYGOSITY; HUMAN; LIVER FUNCTION; LIVER TRANSPLANTATION; LONG TERM CARE; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY; VASCULAR DISEASE; XANTHOMA;

CHOLESTEROL; FEMALE; HEART TRANSPLANTATION; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIVER TRANSPLANTATION; MIDDLE AGED; PLASMA EXCHANGE; TRIGLYCERIDES; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 0035179398     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2001.150612.x     Document Type: Article

References (30)

1. Familial hypercholesterolemia
2. Pharmacological and surgical treatment of dyslipidemic children and adolescents
3. Plasma exchange in the management of homozygous familial hypercholesterolemia
4. Application of specific extracorporal removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia
5. Selective continuos extracorporal elimination of low density lipoproteins from plasma by heparin precipitation without cations
6. Selective removal of low density lipoprotein by plasma-pheresis in familial hypercholesterolemia
7. Lowering of cholesterol absorption and blood levels by ileal exclusion
8. Reduction in cholesterol and low-density-lipoprotein synthesis after portocaval shunt surgery in a patient with homozygous familial hypercholesterolemia
9. Portocaval shunt in patients with familial hypercholesterolemia
10. Liver transplantation to provide low density lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia
11. Heart-liver transplantation in a patient with familial hypercholesterolemia
12. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia
13. Radical therapy for refractory hyperlipemia
14. Combined transplantation of heart and liver
15. Combined transplantation of heart and liver from two different donors in a patient with type IIa hypercholesterolemia
16. Successful treatment of angina pectoris with liver transplantation and bilateral internal mammary bypass graft surgery in familial hypercholesterolemia
17. Normal levels of lipoprotein including lipoprotein (a) after liver-heart transplantation in a patient with homozygous familial hypercholesterolemia
18. Liver transplantation for familial hypercholesterolemia before the onset of cardiovascular complications
19. Liver transplantation for homozygous familial hypercholesterolemia
20. Orthopic liver transplantation for hepatic-based metabolic disorders
21. Genetics of the low-density lipoprotein receptor. Low density lipoprotein receptor activity in cultured fibroblasts from subjects with or without familial hypercholesterolemia
22. Two founder mutations in LDL receptor gene in Norwegian family hypercholesterolemia subjects
23. Plasma exchange in two receptor negative homozygous for autosomal, dominant hypercholesterolemia
24. Sixteen years of plasma exchange in a homozygous familial hypercholesterolemia
25. Studies on the orthopic homotransplantation of the canine heart
26. Homotransplantation of liver in humans
27. Hyperlipidemia in solid organ transplantation
28. HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: Evidence for antigen-independent mechanisms?
29. Effects of pravastatin on outcomes after cardiac transplantation
30. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial